Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
复制标题
DOI：
10.3748/wjg.v23.i6.1090
复制
发表时间：
2017-02-14
影响因子：
4.3
通讯作者：
Ando Y
中科院分区：
文献类型：
--
作者：
Maeda O;Matsuoka A;Miyahara R;Funasaka K;Hirooka Y;Fukaya M;Nagino M;Kodera Y;Goto H;Ando Y
评价化疗的可行性，包括氟嘧啶，铂和紫杉烷与修改剂量的不可切除的胃癌患者在日本。我们对改良的多西他赛、顺铂和卡培他滨（DCX）方案治疗IV期胃癌进行了可行性研究。具体而言，第1天给予30或40 mg/m2多西他赛，第1天给予60 mg/m2顺铂，每3周给予2000 mg/m2卡培他滨，持续2周。3例患者接受改良DCX（mDCX）30 mg/m2多西他赛治疗，5例患者接受该方案40 mg/m2多西他赛治疗。在8例患者中的6例中观察到3级或4级中性粒细胞减少;无患者表现出发热性中性粒细胞减少。8例患者中有4例获得部分缓解。3例患者接受胃切除术，实现了R 0切除，清扫的淋巴结中无残留肿瘤。在这3例患者中，1例切除标本显示原发病灶和淋巴结病理完全缓解。日本IV期胃癌患者对mDCX的耐受性良好。该方案可能有助于使有远处淋巴结转移的胃癌患者接受转换手术。
To evaluate the feasibility of chemotherapy including fluoropyrimidine, platinum and taxane with modified dosages for unresectable gastric cancer in Japanese patients. We performed a feasibility study of a modified docetaxel, cisplatin and capecitabine (DCX) regimen for stage IV gastric cancer. In particular, 30 or 40 mg/m2 of docetaxel on day 1, 60 mg/m2 of cisplatin on day 1, and 2000 mg/m2 of capecitabine for 2 wk were administered every three weeks. Three patients were treated with modified DCX (mDCX) with 30 mg/m2 docetaxel, and five patients were treated with this regimen with 40 mg/m2 docetaxel. Grade 3 or 4 neutropenia was observed in six of the eight patients; no patients exhibited febrile neutropenia. Partial response was achieved in four of the eight patients. Three patients underwent gastrectomy, which achieved R0 resection without residual tumors in dissected lymph nodes. In one of these three patients, resected specimens revealed pathological complete response in the primary lesion and in lymph nodes. mDCX was well tolerated by Japanese patients with stage IV gastric cancer. This regimen might be useful for allowing gastric cancer patients with distant lymph node metastasis to undergo conversion surgery.